Edition:
United States

Antisense Therapeutics Ltd (ANP.AX)

ANP.AX on Australia Stock Exchange

0.03AUD
24 May 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.03
Open
$0.03
Day's High
$0.03
Day's Low
$0.03
Volume
39,891
Avg. Vol
141,708
52-wk High
$0.06
52-wk Low
$0.03

Latest Key Developments (Source: Significant Developments)

Antisense Therapeutics says it initiated process for submission of atl1102 for multiple sclerosis phase iib
Sunday, 23 Apr 2017 09:41pm EDT 

April 24 (Reuters) - Antisense Therapeutics Ltd :Initiated process for submission of atl1102 for multiple sclerosis (ms) phase iib ind application with documentation being provided to its regulatory agent in us.  Full Article

Antisense Therapeutics announces ATL1103 granted orphan drug designation in Europe
Monday, 27 Jun 2016 07:10pm EDT 

Antisense Therapeutics Ltd : ATL1103 granted orphan drug designation in Europe . European commission grants orphan medicinal product designation for acromegaly drug in the European union .  Full Article

Antisense Therapeutics gets orphan drug designation from FDA for ATL1103
Wednesday, 11 May 2016 07:37pm EDT 

Antisense Therapeutics Ltd : Orphan drug designation from FDA for atl1103 in acromegaly Full Article

Antisense Therapeutics intends to seek orphan drug designation for COR-004
Sunday, 9 Aug 2015 07:23pm EDT 

Antisense Therapeutics Ltd:Intends to seek orphan drug designation for COR-004 from the FDA and the EMA.  Full Article

More From Around the Web

No consensus analysis data available.